http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-104307-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a7ac31dafa9b644bcbf73f79c4695dc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D497-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-96 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 |
| filingDate | 2016-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87bdbfdcd3b61bedbe7f9f23049b0819 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a529845fc4293e826fc17529dfa7159f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68962848254e5a26aeb4483b326bb91b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f77f414f78bf44ce188a0965c0a406ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a03460c57fa9023aa3630766ee446031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d758272fa0085de58abd738e82f0cd01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_444229e6805415f172df1926878e5ca6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_997b0e98fc942e991cc674429918a4f3 |
| publicationDate | 2017-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-104307-A1 |
| titleOfInvention | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINES AS HDAC INHIBITORS |
| abstract | This refers to histone deacetylase inhibitors (HDACs) such as HDAC6 and HDAC11 and their use in the treatment of diseases such as cell proliferative diseases (for example, cancer), neurological disease (for example, neurodegenerative disease or neuroevolutive disease), inflammatory or autoimmune disease, infection, metabolic disease, hematological disease or cardiovascular disease. Claim 1: A compound of the formula (1), X¹, X², X³, X⁶ and X⁷ are each, independently, -CR¹R²-, -NR³-, -O-, -C (O) -, -SO₂ -, -S (O) - or -S-; X⁴ and X⁵ are each, independently, -CR¹R²-, -C (O) -, -SO₂-, -S (O) - or -S-; Y¹, Y² and Y⁴ are each, independently, N or CR¹; L is a link, - (CR¹R²) ₙ-, -C (O) NR³-, -S (O) ₂-, -S (O) ₂NR³-, -S (O) -, -S (O) NR³- , -C (O) (CR¹R²) ₙO- or -C (O) (CR¹R²) ₙ-; R is, independently, -H, -C₁₋₆ alkyl, -C₂₋₆ -alkenyl, -Cc -cycloalkenyl, -Cquin -alkyl, -C₃₋₈ -cycloalkyl, -spirocyclo-Coc, heterocyclyl, spiroheterocyclyl, aryl or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P or O, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, spirocyclo, heterocyclyl, spiroheterocyclyl, aryl or heteroaryl optionally is substituted with one or several -OH, halogen, oxo, -NO₂, -CN, -R¹, -R², -SR³, -OR³, -NHR³, -NR³R⁴, -S (O) ₂NR³R⁴, -S (O) ₂R¹, -C ( O) R¹, -CO₂R¹, -NR³S (O) ₂R¹, -S (O) R¹, -S (O) NR³R⁴, -NR³S (O) R¹, heterocycle, aryl or heteroaryl; R¹ and R² are, independently, at each occurrence, -H, -R³, -R⁴, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₄₋₈ -cycloalkenyl, -C₂₋₆ -alkynyl, -C₃₋ -cycloalkyl ₈, heterocyclyl, aryl, heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P and O, -OH, halogen, -NO₂, -CN, -NH-C₁₋₆ alkyl, -N (alkyl C₁₋₆) ₂, -S (O) ₂N (C₁₋₆ alkyl) ₂, -N (C₁₋₆ alkyl) S (O) ₂R⁵, -S (O) ₂ (C₁₋₆ alkyl), - (alkyl C₁₋₆) S (O) ₂R⁵, -C (O) C₁₋₆ alkyl, -CO₂-C₁₋₆ alkyl, -N (C₁₋₆ alkyl) S (O) ₂-C₁₋₆ alkyl or (CHR⁵) NR-NR³R⁴, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more -OH, halogen, -NO₂, oxo, -CN, -R⁵, -OR³, NHR³, NR³R⁴, S (O) ₂N (R³) ₂-, -S (O) ₂R⁵, -C (O) R⁵, -CO₂R⁵, -NR³S (O) ₂R⁵, -S (O) R⁵, -S (O) NR³R⁴ , -NR³S (O) R⁵, heterocycle, aryl or heteroaryl; or R¹ and R² can be combined with the carbon atom to which they are attached to form a cycloalkyl, heterocycle, spirocycle, spiroheterocycle or spirocycloalkenyl; or R¹ and R², when they are in adjacent or non-adjacent atoms, can be combined to form a heterocycle, cycloalkyl, aryl, heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P and O or cycloalkenyl; R³ and R⁴ are, independently, at each occurrence, -H, -C₁₋₆ alkyl, -C₂₋₆ -alkenyl, -Cc -cycloalkenyl, -Cquin -alkynyl, -C₃₋₈ -cycloalkyl, heterocyclyl, aryl, heteroaryl containing 1-5 heteroatoms selected from N, S, P and O, -S (O) ₂N (C₁₋₆ alkyl) ₂, -S (O) ₂ (C₁₋₆ alkyl), - (C₁₋₆ alkyl ) S (O) ₂R⁵, -C (O) C₁₋₆ alkyl, -CO₂-C₁₋₆ alkyl or - (CHR⁵) ₙN (C₁₋₆ alkyl) ₂, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl , heterocyclyl, aryl and heteroaryl is optionally substituted with one or more substituents selected from -OH, halogen, -NO₂, oxo, -CN, -R⁵, -O-C₁₋₆ alkyl, -NH-C₁₋₆ alkyl, -N (C₁₋₆ alkyl) ₂, -S (O) ₂N (C₁₋₆ alkyl) ₂, -S (O) ₂NH-C₁₋₆ alkyl, -C (O) C₁₋₆ alkyl, -CO₂-C₁₋ alkyl ₆, -N (C₁₋₆ alkyl) S (O) ₂-C₁₋₆ alkyl, -S (O) R⁵, -S (O) N (C₁₋₆ alkyl) ₂, -N (C₁₋ alkyl ) S (O) R⁵, heterocycle, aryl or heteroaryl; R⁵ is, independently, at each occurrence, -H, -C₁₋₆ alkyl, -C₂₋₆ -alkenyl, -C₄₋₈ -cycloalkenyl, -Cquin -alkyl, -C₃₋₈ -cycloalkyl, heterocyclyl, aryl, heteroaryl which contains 1-5 heteroatoms selected from N, S, P and O, -OH, halogen, -NO₂, -CN, -NH-C₁₋₆ alkyl, -N (C₁₋₆ alkyl) ₂, - S (O) ₂NH (C₁₋₆ alkyl), -S (O) ₂N (C₁₋₆ alkyl) ₂, -S (O) ₂ -C alquilo alkyl, -C (O) C₁₋₆ alkyl, -CO₂-C₁₋₆ alkyl , -N (C₁₋₆ alkyl) SO₂-C₁₋₆ alkyl, -S (O) (C₁₋₆ alkyl), -S (O) N (C₁₋₆ alkyl) ₂, -N (C₁₋₆ alkyl) S (O) (C₁₋₆ alkyl) or - (CH₂) ₙN (C₁₋₆ alkyl) ₂; n is an integer from 0 to 6; and m is 0, 1, 2 or 3. |
| priorityDate | 2015-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.